Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: the paradigm of radiotherapy
Advances in cancer therapeutics have improved patient survival rates. However, cancer
survivors may suffer from adverse events either at the time of therapy or later in life …
survivors may suffer from adverse events either at the time of therapy or later in life …
CCL2 signaling promotes skeletal muscle wasting in non-tumor and breast tumor models
N Alissa, WB Fang, M Medrano… - Disease Models & …, 2024 - journals.biologists.com
Despite advancements in treatment, approximately 25% of patients with breast cancer
experience long-term skeletal muscle wasting (SMW), which limits mobility, reduces drug …
experience long-term skeletal muscle wasting (SMW), which limits mobility, reduces drug …
Mutant RAS-driven Secretome Causes Skeletal Muscle Defects in Breast Cancer
Cancer-induced skeletal muscle defects differ in severity between individuals with the same
cancer type. Cancer subtype-specific genomic aberrations are suggested to mediate these …
cancer type. Cancer subtype-specific genomic aberrations are suggested to mediate these …